Quatramer is tumor-targeted platform with capacity to deliver drug and biologic combinations
Our therapies are designed to improve the targeting of a variety of therapeutic drug candidates by enhancing the uptake of anticancer agents in the tumor microenvironment with an extended duration of action and minimal off-target toxicity. Quatramer offers the potential to significantly improve the profile and widen the therapeutic window of small molecules, peptides, cytokines and oligomers preferentially delivered to tumors. Quatramer building blocks are pH-triggered to degrade intra-cellularly and are comprised of FDA inactive ingredients.
Our formulations, technology and new chemical entity (NCE) global patent protections create heightened barriers to market entry along with manufacturing process know-how.